This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
The PALOMA-3 OS final analysis of IBRANCE in combination with fulvestrant in 1st line or later demonstrated a numerical difference in favour of IBRANCE in combination with fulvestrant vs placebo + fulvestrant that did not reach statistical significance1,2
The difference in median OS with IBRANCE in combination with fulvestrant (not statistically significant)1 was similar to the improvement in mPFS previously seen with the addition of IBRANCE to fulvestrant in PALOMA-31,3
Adapted from IBRANCE SmPC2 and Turner NC, et al. 2018.1
Data cut-off date: April 13, 2018.
The final updated non-prespecified OS analysis demonstrated a numerical difference in mOS in favor of IBRANCE + fulvestrant, at >6 years median follow-up.⁴
Data cut-off date: August 17, 2020.
See PALOMA-2 overall survival data
What do experts think about the efficacy of IBRANCE?
Expert opinion (Placeholder for local video content)
Discover how patients responded to IBRANCE combination therapy in the real-world setting
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023